152 related articles for article (PubMed ID: 29688882)
21. Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada.
Knowles SR; Lee K; Paterson JM; Shah BR; Mamdani MM; Juurlink DN; Gomes T
Can J Diabetes; 2017 Apr; 41(2):138-142. PubMed ID: 27989494
[TBL] [Abstract][Full Text] [Related]
22. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
23. Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada.
Shayegan B; Wallis CJD; Malone S; Cagiannos I; Hamilton RJ; Ferrario C; Gotto GT; Basappa NS; Morgan SC; Fernandes R; Morash C; Niazi T; Noonan KL; Rendon R; Osborne B; Park-Wyllie L; Chan KFY; Hotte SJ; Saad F
Urol Oncol; 2022 May; 40(5):192.e1-192.e9. PubMed ID: 35216890
[TBL] [Abstract][Full Text] [Related]
24. Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.
Hasan H; Howard F; Morgan SG; Metzger DL; Lo AC; Goddard K; Gill S; Johnson M
Healthc Policy; 2014 Feb; 9(3):80-96. PubMed ID: 24726076
[TBL] [Abstract][Full Text] [Related]
25. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
Francini E; Sweeney CJ
Eur Urol; 2016 Sep; 70(3):410-2. PubMed ID: 27184379
[TBL] [Abstract][Full Text] [Related]
27. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
28. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
29. State of provincial regulations and guidelines to promote low impact development (LID) alternatives across Canada: Content analysis and comparative assessment.
Ishaq S; Hewage K; Farooq S; Sadiq R
J Environ Manage; 2019 Apr; 235():389-402. PubMed ID: 30708276
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of metastatic, castration-resistant prostate cancer].
von Amsberg G; Merseburger AS
Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
[TBL] [Abstract][Full Text] [Related]
31. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
32. Is there still a place for docetaxel rechallenge in prostate cancer?
Petrioli R; Francini E; Roviello G
World J Clin Oncol; 2015 Oct; 6(5):99-103. PubMed ID: 26468445
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
34. Systemic treatment for metastatic prostate cancer.
Gravis G
Asian J Urol; 2019 Apr; 6(2):162-168. PubMed ID: 31061802
[TBL] [Abstract][Full Text] [Related]
35. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
36. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
Jackson EB; Hotte SJ
Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
[TBL] [Abstract][Full Text] [Related]
37. Measuring progress in cancer survival across Canadian provinces: Extending the cancer survival index to further evaluate cancer control efforts.
Ellison LF
Health Rep; 2022 Jun; 33(6):17-29. PubMed ID: 35876613
[TBL] [Abstract][Full Text] [Related]
38. A scorecard for osteoporosis in Canada and seven Canadian provinces.
Kendler DL; Adachi JD; Brown JP; Juby AG; Kovacs CS; Duperrouzel C; McTavish RK; Cameron C; Slatkovska L; Burke N
Osteoporos Int; 2021 Jan; 32(1):123-132. PubMed ID: 32712739
[TBL] [Abstract][Full Text] [Related]
39. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S
J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
